Many of the top large-cap device makers reported relatively rosy fourth-quarter earnings while issuing 2023 guidance that was above analyst expectations.

Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...

Analyst Nico Chen of DBS maintained a Hold rating on Medtronic (MDT – Research Report), retaining the price target of $90.00. Nico Chen ...

Medtronic announced results from a survey indicating that AI and VR could help reduce disparities in access to surgical ...

Medtronic (MDT) said it has voluntarily recalled its MiniMed 600 and 700 series insulin pumps over reports of shortened ...

医疗器械制造商美敦力（Medtronic）的高管表示，该公司非常看好生成式人工智能的应用前景，因此公司要求每个部门研究如何利用这项技术提高生产率，或者改善患者的治疗效果。

Medtronic (NYSE:MDT – Free Report) had its price target increased by Truist Financial from $90.00 to $93.00 in a report issued on Monday, Benzinga reports. The firm currently has a hold rating on the ...

Major medical device manufacturing company Medtronic has announced a US Food and Drugs Administration (FDA) class I recall of ...

Medtronic in Santa Ana says its layoffs are temporary while it repairs a roof, while Avante in San Clemente wades through ...

Medtronic is a compelling investment with its diverse revenue streams, strong growth, and promising product pipeline at an ...

The FDA approved an early feasibility study of Medtronic’s Affera mapping and ablation system and Sphere-9 catheter in patients with ventricular tachycardia, an abnormal heart rhythm.

Medtronic Plc announced a voluntary recall Friday of certain insulin pumps after customers said a single drop, bump, or ...